Role of metformin in suppressing 1,2-dimethylhydrazine-induced colon cancer in diabetic and non-diabetic mice: Effect on tumor angiogenesis and cell proliferation

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Zaafar, Dalia K ^a   Zaitone, Sawsan A ^b   Moustafa, Yasser M ^b  

^a Directorate of Health and Population   (Egypt)

^b Suez Canal University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DIMETHYLHYDRAZINE; CD34 ANTIGEN; GLUCOSE; INSULIN; KI 67 ANTIGEN; METFORMIN; OXALIPLATIN; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN; 1,2 DIMETHYLHYDRAZINE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; SOMATOMEDIN C; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HOMEOSTASIS MODEL ASSESSMENT INDEX FOR INSULIN RESISTANCE INDEX; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INSULIN BLOOD LEVEL; MALE; METABOLIC PARAMETERS; MONOTHERAPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK REDUCTION; SURVIVAL RATE; ANIMAL; BLOOD; CELL PROLIFERATION; CHEMICALLY INDUCED; COLON; COLONIC NEOPLASMS; DIABETES MELLITUS, EXPERIMENTAL; DRUG COMBINATION; DRUG EFFECTS; LIPID DIET; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

1,2-DIMETHYLHYDRAZINE; ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; COLON; COLONIC NEOPLASMS; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; DRUG THERAPY, COMBINATION; HYPOGLYCEMIC AGENTS; INSULIN-LIKE GROWTH FACTOR I; MALE; METFORMIN; MICE; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; RECEPTOR, IGF TYPE 1; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903537513     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100562     Document Type: Article

References (67)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics. CA Cancer J Clin 58:71-96.
2. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of U.S. adults. Am J Epidemiol 159: 1160-1167. (Pubitemid 38747263)
3. El-Serag H, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4: 369-380. (Pubitemid 43343895)
4. Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97: 1679-1687. (Pubitemid 41672234)
5. Friberg E, Orsini N, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50: 1365-1374. (Pubitemid 46879010)
6. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31.
7. Hanahan D (1998) A flanking attack on cancer. Nat Me 4: 13-14.
8. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, et al. (2004) Vascular Endothelial Growth Factor and Angiogenesis. Pharmacol Rev 56: 549-580. (Pubitemid 39658463)
9. Chiarelli F, Spagnoli A, Basciani F, Tumini S, Mezzetti A, et al. (2000) Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycemic control and microvascular complications. Diabet Med 17: 650-656.
10. Ferrara N, Houck K, Jakeman L, Leung DW (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13: 18-32.
11. Ikemura M, Nishikawa M, Kusamori K, Fukuoka M, Yamashita F, et al. (2013) Pivotal role of oxidative stress in tumor metastasis under diabetic conditions in mice, Sakyo-ku, Kyoto. Jap J Controlled Release 170: 191-197.
12. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
13. Boyd DB (2003) Insulin and cancer. Integr Cancer Ther 2: 315-329.
14. Haisa M (2013) The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer. J Int Med Res 41: 253-264.
15. Arcaro A (2013) Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol 4: 1-8.
16. Micic D, Cvijovic G, Trajkovic V, Duntas LH, Polovina S (2011) Hormones. 10: 5-15.
17. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305. (Pubitemid 40813563)
18. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258. (Pubitemid 44106500)
19. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, et al. (2009) New users of metformin are at Low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625.
20. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, et al. (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297-3302.
21. McFarland MS, Cripps R (2010) Diabetes Mellitus and Increased Risk of Cancer: Focus onMetformin and the Insulin Analogs. Pharmacotherapy: J Human Pharmacol Drug Therapy 30: 1159-1178.
22. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P (2005) Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening. Pharmacol Res 52: 313-320. (Pubitemid 41175991)
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetol 28: 412-419. (Pubitemid 15018832)
24. Colussi C, Fiumicino S, Giuliani A, Rosini S, Musiani P, et al. (2001) 1,2-dimethylhydrazine-induced colon carcinoma and Lymphoma in msh2-/-mice. JNCI 93: 1534-1540. (Pubitemid 32998482)
25. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V (2011) Metformin Suppresses Ovarian Cancer Growth and Metastasis with Enhancement of Cisplatin Cytotoxicity In Vivo. Neoplasia 13: 483-491.
26. Reagan-Shaws, Nihal M, Ahmed N (2008) Translation from animal to human studies revisited. FASEB J 22:659-661.
27. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V (2011) Metformin Suppresses Ovarian Cancer Growth and Metastasis with Enhancement of Cisplatin Cytotoxicity In Vivo. Neoplasia 13(5): 483-491.
28. Liu J, Li M, Song B, Jia C, Zhang L, et al. (2013) Metformin inhibits renal cell carcinoma in vitro and in vivo xenografts. Urol Oncol: Seminars and Original Invest 31: 264-270.
29. Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, et al. (2011) In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol 668: 373-382.
30. Rothenberg ML (2000) Efficacy of oxaliplatin in treatment of colorectal cancer, Oncology 14(11): 9-14.
31. th Ed. Churchil Livingstone, New York, London, San Francisco, Tokyo.
32. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16: 1103-1123.
33. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, et al. (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan, Arch. Intern Med 166: 1871-1877. (Pubitemid 44455170)
34. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, et al. (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. J Am Med Assoc 300: 2754-2764.
35. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, et al. (2003) Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 26: 1752-1758. (Pubitemid 36929115)
36. Will JC, Galuska DA, Vinicor F, Calle EE (1998) Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 147: 816-825. (Pubitemid 28244386)
37. Everhart J, Wright D (1995) Diabetes mellitus as risk factor for pancreatic cancer: a meta-analysis. JAMA 273: 1605-1609.
38. Awata K, Inoue K, Kurihara S, Ohkubo T, Watanabe M, et al. (2002). A Common Polymorphism in the 5′-Untranslated Region of the VEGF Gene Is Associated With Diabetic Retinopathy in Type 2 Diabetes. Diabetes 51: 1635-1639. (Pubitemid 34826636)
39. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353. (Pubitemid 38529873)
40. Gerstein HC (2010) Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA 303: 446-447.
41. Hvid H, Blouin MJ, Birman E, Damgaard J, Poulsen F, et al. (2013) Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts. PLoS ONE 8:e79710.
42. Kisfalvi K, Eibl G, Sinnet-Smith J, Rozengurt E (2009) Metformin disrupts crosstalk between G protein coupled-receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69: 2539-2545.
43. Oh JS, Kucab JE, Bushel PR, Martin K, Bennett L, et al. (2002) Insulin-like growth factor-I inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia 4: 204-217. (Pubitemid 34525252)
44. Castleden, Shilkin Br (1979) Diet, liver function and dimethylhydrazine-induced gastrointestinal tumours in Wistar rats. J Cancer 39: 731-739.
45. Lewis JG, James A (1982) Effect of 1,2-Dimethylhydrazine and diethyl nitrosamine on Cell Replication and Unscheduled DMA Synthesis in Target and Non target Cell Populations in Rat Liver Following Chronic Administration. Cancer Res 42: 89-92. (Pubitemid 12207253)
46. Ying TS, Sarma DS, Farber E (1979) Induction of presumptive preneoplastic lesions in rat liver by a single dose of 1,2-dimethylhydrazine. Chem. Biol. Interact 28: 363-366. (Pubitemid 10199511)
47. Hayes MA, Rushmore TH, Goldberg MI (1987) inhibition of hepatocarcinogenic response to 1,2dimethylhydrazine by diallyl sulfide, a component of garlic oil. Carcinogenesis, 8:1155-1157.
48. Yilmaz A, Davis ME, Simmen RCM (1999) Reproductive performance of bulls divergently selected on the basis of blood serum insulin-like growth factor I concentration. J Anim Sci 77: 835-839. (Pubitemid 129558797)
49. Jackson PE, Cooper DP, O'Connor PJ, Povey AC (1999) The relationship between 1,2-dimethylhydrazine dose and the induction of colon tumors: tumor development in female SWR mice does not require a K-ras mutational event. Carcinogenesis 20: 509-513. (Pubitemid 29112642)
50. Bhattacharyya S, Sul K, Krukovets I, Nestor C, Li J, et al. (2012) Novel Tissue-Specific Mechanism of Regulation of Angiogenesis and Cancer Growth in Response to Hyperglycemia. J Am Heart Assoc.
51. Ito K, Ishigamori R, Mutoh M, Ohta T, Imai T, et al. (2013) Ay allele promotes azoxymethane-induced colorectal carcinogenesis by macrophage migration in hyperlipidemic/diabetic KK mice. Cancer Sci. 104(7):835-43.
52. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, et al. (2003) Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348: 2294-2303. (Pubitemid 36638103)
53. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, et al. (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653. (Pubitemid 41817713)
54. Martin A, Komada MR, Sane DC (2003) Abnormal angiogenesis in diabetes mellitus. Med Res Rev 23: 117-145. (Pubitemid 36241095)
55. Stenina OI (2005) Regulation of vascular genes by glucose. Curr Pharm Des 11: 2367-2381.
56. Ferguson RD, Novosyadlyy R, Fierz Y, Alikhani N, Sun H, et al. (2012) Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res 14: R8.
57. Yabe Y, Kobayashi N, Nishihashi T, Takahashi R, Nishikawa M, et al. (2001) Prevention of neutrophil-mediated hepatic ischemia/reperfusion injury by superoxide dismutase and catalase derivatives. J Pharmacol Exp Ther 298: 894-899. (Pubitemid 32761901)
58. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947. (Pubitemid 30644117)
59. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, et al. (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147. (Pubitemid 30036347)
60. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69: 7507-7511.
61. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, et al. (2005) Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neutransgenic mice. Exp Gerontol 40: 685-693. (Pubitemid 41265819)
62. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, et al. (2010) Metformin prevents tobacco carcinogen-induced lung tumorgenesis. Cancer Prev Res 3: 1066-1076
63. Saito T, Chiba T, Yuki K, Zen Y, Oshima M, et al. (2013) Metformin, a Diabetes Drug, Eliminates Tumor-Initiating Hepatocellular Carcinoma Cells. Plos one 8:e70010.
64. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, et al. (2008) Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 99: 2136-2141.
65. Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, et al. (2010) Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinogenesis 49: 662-671.
66. Shank JJ, Yang K, Ghannam J, Cabrera L, Johnston CJ, et al. (2012) Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol 127: 390-397.
67. Landman GW, Kleefstra N, Kornelis JJ, Groenier KH, Gans ROP, et al. (2009) the American Diabetes Association. Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes. Diabetes care 33: 322-326.